IMI offers €12.2m for better ways of testing effectiveness of flu vaccines
This article was originally published in Scrip
€12.2m in EU funding is being made available for new ideas on how to develop standardised tests that can more accurately determine how effective a new influenza vaccine is likely to be. The funding is being offered by Europe's Innovative Medicines Initiative (IMI), a joint undertaking between the pharmaceutical industry federation EFPIA and the European Commission.
You may also be interested in...
UK proposals for limited cooperation with the EU in medicines regulation, including the recognition of certificates and inspections, are one glimmer of light in an otherwise uncertain post-Brexit regulatory scenario for the UK. But time pressures and political spats over the future relationship could throw the whole enterprise into doubt.
The coronavirus could have serious adverse effects on regulatory procedures at both European Medicines Agency and EU member state level. A new business continuity plan describes how procedures will be prioritized if problems arise.
Coronavirus Update: Setback With Hydroxychloroquine, Slowdown In UK ADR Reports, But Novel Drugs Begin Trials
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.